India's Health Minister Dr. Harsh Vardhan has said that Kovid-19 vaccine can be started by people from January next year. He said that the first priority of the government is to ensure that the vaccine is safe and effective.
"I think the time may come in January when we will be in a position to give the corona vaccine to the common people."
The Health Minister said that the drug regulator is currently analyzing all other vaccines, including the Corona vaccine applied for use in the Emergency.
He said, "India is second to none in the research of the vaccine of Kovid-19. Our first priority is that the vaccine is completely safe and it should be effective against this virus. In this case we do not want compromise "Our regulators are analyzing the data associated with the vaccine in view of everything."
Dr. Harsh Vardhan said on Saturday that work is going on on indigenous vaccine in the country as well and it is expected that in the coming six to seven months we will be able to give vaccine doses to 300 million people in the country.
At the 22nd meeting of the High-Level Group of Ministers (GoM) on Kovid-19, he said, "Our scientists and health experts have isolated the virus and sequenced its genome and after that they are working on making its indigenous vaccine. In the coming six to seven months we will have the capacity to provide vaccines to 300 million people. "
According to the Health Ministry, there are currently nine Corona vaccines being made in the country, which are at different levels of clinical trials.
Six of these clinical trials are going on, while three are currently at the pre-clinical trial level.
Astrozenica is producing this vaccine made by Kovishield - Oxford University. The Pune-based Serum Institute is its Indian partner for this vaccine to be made on the chimpanzee adenovirus platform. Clinical trials for the second and third phases of this are going on and permission has been sought from the government for its emergency use.
Kovacine - This is a vaccine produced using dead virus, which is being developed by Hyderabad-based Bharat Biotech. In the third phase clinical trials are going on with the help of ICMR and permission has been sought from the government for its emergency use.
ZyCoV-D - This vaccine from Cadila Healthcare is being made on the DNA platform. Cadila has collaborated with the Department of Biotechnology for this. Clinical trials of its third phase are underway.
Sputnik-V - This is a vaccine produced by the Gamalaya National Center of Russia, which is being made on the Human Adenovirus platform. It is produced on a large scale by the Doctor Radies Lab of Hyderabad. This vaccine has reached the Phase III clinical trial.
NVX-CoV2373 - This vaccine, being made on the basis of a protein fragment of the virus, is being produced by Serum Institute, Pune. For this, the institute has collaborated with Novavax. Clinical trials of its third phase are currently being considered.
American-based MIT-produced Protein Antigen Based Vaccine is being produced by Biological e Limited of Hyderabad. Human clinical trials of the first and second phases have started.
HGCO 19 - The US-based HDT mRNA-based vaccine is being produced by Pune-based company called Genova. Experiments on animals regarding this vaccine have ended and soon clinical trials of the first and second phases are about to begin.
Bharat Biotech, based in Hyderabad, in collaboration with Thomas Jefferson University of America, is producing the corona vaccine based dead rabies vector platform. This vaccine has reached the advanced pre-clinical level.
India's Aurobindo Pharma has remained a vaccine in association with American's Aurovaccine, which is currently at the pre-development stage.